Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 117 of 151

  1. SPD557

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule terminated

    1 trial

  2. SPD602

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule terminated

    2 trials

  3. SPD602

    Takeda

    Iron Overload Due to Repeated Red Blood Cell Transfusions

    phase 2 small molecule terminated

    1 trial

  4. SPD602 (FBS0701, SSP-004184)

    Takeda

    Transfusional Iron Overload

    phase 2 small molecule completed

    1 trial

  5. SPGL008

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NMIBC

    phase 2 mab active

    1 trial

  6. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  7. SPI-62-CL-2003

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica (PMR)

    phase 2 small molecule active

    1 trial

  8. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  9. SPINALON (buspirone + levodopa + cardidopa)

    United Therapeutics Europe Ltd

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  10. SPLFIO-174

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  11. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  12. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  13. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Impulsive Aggression Comorbid With ADHD

    phase 2 small molecule completed

    1 trial

  14. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    2 trials

  15. SPN-817

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  16. SPN-821 2400 mg

    SUPERNUS PHARMACEUTICALS, INC.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  17. SPON - 1751-19

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  18. SPR001

    SPRUCE BIOSCIENCES, INC.

    Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    2 trials

  19. SPR720

    Spero Therapeutics

    Mycobacterium Avium Complex

    phase 2 small molecule terminated

    1 trial

  20. SPRINKLE D1346C00004

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)

    phase 2 small molecule active

    1 trial

  21. SPT-300

    Seaport Therapeutics

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    2 trials

  22. SPT-300-2024-204

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  23. SPY001

    Spyre Therapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  24. SPY002-072

    Spyre Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  25. SPY123-201

    Spyre Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  26. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial

  27. SR-T100 ® Gel

    Biotech Pharmaceutical Co.,

    Actinic Keratosis

    phase 2 small molecule completed

    1 trial

  28. SR419

    Shanghai University of Traditional Chinese Medicine

    Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  29. SRA-MMB-4365/219627

    GlaxoSmithKline

    Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

    phase 2 other active

    1 trial

  30. SRF388

    Coherus Oncology

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  31. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  32. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  33. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  34. SRP-5051

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 2 small molecule terminated

    2 trials

  35. SRP-9003

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2E

    phase 2 gene therapy terminated

    1 trial

  36. SRP-9004

    Sarepta Therapeutics

    Limb-Girdle Muscular Dystrophy, Type 2D

    phase 2 gene therapy completed

    1 trial

  37. SRX246

    United Therapeutics Europe Ltd

    PTSD

    phase 2 small molecule terminated

    1 trial

  38. SS-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  39. SS-1

    Hospital Authority, Hong Kong

    Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  40. SSGJ-611-PED-AD-Ib/II-01

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Dermatitis, Atopic

    phase 2 small molecule active

    1 trial

  41. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials

  42. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  43. SSGJ-706+XELOX

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gastric/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  44. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  45. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  46. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    NSCLC

    phase 2 small molecule active

    1 trial

  47. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  48. SSP-002358 (0.1 mg) + PPI

    Takeda

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.